Skip to content
Business

Telix Agrees to Buy Munich Isotope Maker ITM for Up to $2.35bn

Australia's Telix Pharmaceuticals agreed to buy ITM Isotope Technologies Munich for $1.65 billion upfront, mostly in shares, plus up to $700 million tied to its lead cancer drug.

An ITM lab worker in safety glasses and blue gloves pipettes a sample behind a clear protective shield.
Photo: ITM Isotope Technologies Munich

Australia's Telix Pharmaceuticals agreed to buy ITM Isotope Technologies Munich for $1.65 billion upfront and up to $700 million more in milestone payments, bringing the privately held German maker of cancer-treatment isotopes into a larger listed radiopharmaceutical group.

Most of the upfront price is paid in stock. Telix will issue 105.8 million new shares worth $1.25 billion, priced at $11.841 each, the 30-day volume-weighted average at signing. It will also assume $302 million of ITM's net debt at closing. Once the deal completes, ITM's shareholders will own 23.7 percent of the combined company and Telix's existing investors 76.3 percent.

Deal componentAmountTerms
Upfront consideration$1.65bnCash-free, debt-free basis; includes $1.25bn in Telix shares
FDA approval milestonesUp to $250mApprovals in three indications, within set deadlines
Sales milestoneUp to $450mIf ITM-11 global net sales top $150m in financial year 2030
Net debt assumed$302mTaken on at closing

The milestones can be paid in cash or shares, at Telix's option. A further $96 million of management equity rollover and seller transaction costs is subject to closing adjustments.

What Telix Is Buying

ITM, founded in 2004, produces radioisotopes used in targeted cancer treatment, including lutetium-177, actinium-225 and terbium-161, and distributes them in more than 65 countries. It runs two GMP manufacturing sites and produces lutetium-177 at commercial scale, covering the chain from raw materials and irradiation to quality control, logistics and delivery.

The business has grown quickly. Revenue reached $273 million in 2025, a compound annual growth rate of 40 percent since 2021, and $156 million in the first half of 2026, most of it from manufacturing. Telix said it expects the manufacturing division to keep growing revenue at double-digit rates and to contribute positively to group earnings from 2027.

Two ITM employees in black ITM-branded jackets talk outside a company building.
Two ITM employees in black ITM-branded jackets talk outside a company building. Photo: ITM Isotope Technologies Munich

The ITM-11 Question

The contingent payments hinge on ITM-11, or lutetium-177 edotreotide, a treatment for gastroenteropancreatic neuroendocrine tumours. It has completed its main Phase III programme, including the COMPETE and COMPOSE trials, but it does not yet have marketing approval.

The drug has hit a hurdle in the US. Telix disclosed that the Food and Drug Administration issued a Complete Response Letter in August 2026 over chemistry, manufacturing and controls, and over the inspection of a third-party facility. The letter identified no clinical or nonclinical deficiencies, and ITM intends to resubmit, though no date was given.

That setback helps explain the shape of the deal. By making $700 million of the price depend on approvals and sales, Telix leaves a large part of the regulatory and commercial risk with ITM's sellers, who are paid in full only if the drug reaches the market and sells well.

A Bet on Consolidation in Radiopharma

Telix chief executive Christian Behrenbruch said the merger "positions Telix at the forefront of the consolidation" taking place as the industry matures.

Radiopharmaceuticals pair a radioactive isotope with a molecule that seeks out tumour cells, delivering radiation directly to the cancer. Large drugmakers have bought into the field in recent years, and a secure supply of medical isotopes, which are hard to make at scale, has become a competitive asset in its own right.

For Telix, which opened a radiopharmaceutical research, manufacturing and treatment facility in Melbourne in July, ITM adds an established European production base, an international distribution network and a late-stage therapy. For Germany's biotech sector, it means one of its fastest-growing private companies will end up inside a group listed in Australia and, through American depositary receipts, on Nasdaq.

What Happens Next

Telix's board has approved the transaction, and holders of more than 90 percent of ITM's shares backed it at signing. Completion still needs approval from Telix shareholders, who are expected to vote at an extraordinary general meeting in November, along with regulatory clearances. Telix expects to close by the end of 2026.

The new shares will be issued as Nasdaq-listed American depositary receipts after escrow periods. Telix listed the main risks as a delay or failure to complete, integration costs, supply-chain constraints, disruption to manufacturing, and the chance that expected synergies and financial benefits do not materialise. Investors will also watch for the timing of ITM-11's resubmission to the FDA, which drives the first $250 million of milestones.

Sources

Related stories

Business

Elliott Builds Stake in Deutsche Telekom and Opposes a T-Mobile US Merger

Activist fund Elliott has built a stake in Deutsche Telekom and wants it to drop a possible merger with T-Mobile US, in which it owns about 54 percent, and buy back more shares…

Business

Viking Therapeutics Raises $575m After Its Obesity Drug Holds Weight Off on Monthly Doses

Viking Therapeutics sold $316m of shares at $35 and $259m of 2% convertible notes, priced a day after data showing patients kept most of their weight loss on monthly or…

Business

Kraig Biocraft Laboratories Ships Its First Commercial Spider Silk Yarn Order

Kraig Biocraft Laboratories has shipped its first commercial order of spider silk yarn to an unnamed sports brand, but gave no volume or price and reported no revenue in the first…

Business

Porsche to Cut 9,000 Jobs in a 'Value Over Volume' Reset

Porsche will cut 9,000 jobs by 2035, about a fifth of its workforce, and push its break-even below 200,000 cars as it chases a 15 percent operating margin after last year's 1.1…

Business

Québecor Makes a C$31bn Cash-and-Share Bid for Telus, Which Warns of Regulatory Risk

Québecor has offered C$6.35 in cash plus 0.17 of its own shares for each Telus share, a bid worth about C$31bn. The Telus board says the price falls short and the regulatory risk…

Business

Tyson Foods Shares Jump 8.7% as Beef Outlook Outweighs a $74m Quarterly Loss

Tyson Foods posted a $74m fourth-quarter net loss and adjusted EPS of $0.61, down 47%, yet its shares closed 8.7% higher on Monday as its 2027 beef outlook pointed to far smaller…

Business

Roche Wins FDA Approval for Breast Cancer Pill Wilserdly After 62% Cut in Progression Risk

The FDA approved Roche's all-pill Wilserdly combination for ESR1-mutated advanced breast cancer after it cut the risk of progression or death by 62%. A ruling on early-stage use is…

Business

ULA Loses Its First Mission as Vulcan Rocket Fails With 40 Amazon Leo Satellites on Board

United Launch Alliance's Vulcan rocket failed about 10 minutes after lift-off on Sunday, and all 40 Amazon Leo satellites were lost. Amazon fell 3.3% on Monday as space stocks…